Forsta AP Fonden Sells 600 Shares of DexCom, Inc. (NASDAQ:DXCM)

Forsta AP Fonden trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 0.7% during the 4th quarter, Holdings Channel reports. The firm owned 83,100 shares of the medical device company’s stock after selling 600 shares during the quarter. Forsta AP Fonden’s holdings in DexCom were worth $6,463,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. B. Riley Wealth Advisors Inc. raised its stake in shares of DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after acquiring an additional 162 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. Riverview Trust Co raised its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the last quarter. Finally, Koa Wealth Management LLC boosted its position in DexCom by 7.7% during the third quarter. Koa Wealth Management LLC now owns 3,770 shares of the medical device company’s stock valued at $253,000 after buying an additional 270 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of DXCM opened at $86.83 on Friday. The company has a 50-day simple moving average of $80.49 and a two-hundred day simple moving average of $76.67. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a market capitalization of $33.92 billion, a PE ratio of 51.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their target price on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $99.29.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.